Loading...
Acquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP.
Piggott, L da Silva, A Robinson, T Santiago-Gómez, Angélica Simões, Bruno M Becker, M Fichtner, I Andera, L Piva, M Vivanco, M
Piggott, L
da Silva, A
Robinson, T
Santiago-Gómez, Angélica
Simões, Bruno M
Becker, M
Fichtner, I
Andera, L
Piva, M
Vivanco, M
Citations
Altmetric:
Abstract
One-third of ER-positive breast cancer patients who initially respond to endocrine therapy become resistant to treatment. Such treatment failure is associated with poor prognosis and remains an area of unmet clinical need. Here we identify a specific post-translational modification that occurs during endocrine resistance and which results in tumour susceptibility to the apoptosis inducer TNF-Related Apoptosis-Inducing Ligand (TRAIL). This potentially offers a novel stratified approach to targeting endocrine resistant breast cancer.
Description
Date
2018-01-23
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 1.56 MB
Keywords
Type
Article
Citation
Acquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP. 2018 Clin. Cancer Res.